Clinical Trials · NCT02518945
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- University at Buffalo
- Enrollment
- 26
- Start date
- Aug 2015
- Locations
- 1 site, United States
- Primary endpoint
- Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.